USE OF BIOMARKERS OF ALZHEIMER'S DISEASE FOR DIAGNOSTIC TESTS AND DRUG SCREENING

摘要

The invention relates to method of diagnosing Alzheimer's disease or detecting a predisposition to Alzheimer's disease including providing a test cell sample from a subject, exposing the test cell sample to labeled amyloid beta peptides, and determining the level of labeled amyloid beta peptides in the test cell sample, wherein lower levels of labeled amyloid beta peptides in the test cell sample compared to a control cell sample are indicative of Alzheimer's disease.